XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
May 01, 2017
Aug. 01, 2016
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Apr. 30, 2015
Intangible Assets [Line Items]            
Received amount           $ 4,000
Receipt of required investment $ 5,000          
Expiry term     11 years      
Required payment of liquidated damages     $ 8,000      
Remaining liability     $ 380      
Expires term, description     The Company exclusively licensed two families of patents relating to hCDR1:One expired on September 22, 2022 (in the US. For all other countries, it expired on February 26, 2022) and the other expired on January 14, 2024.      
Assets remained amount     $ 380 $ 380 $ 380  
License agreement, description     Under the license agreement, the Company is required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical trial, $1 million upon FDA approval to market in the U.S., and $250,000 for marketing approval in each of China and three of the European Union’s Group of Five. In addition, the Company is required to pay 2%-3% royalties of annual net sales and sublicense fees of 15%-20% of whatever it receives from any sub-licensee.      
Bottom of Range [Member]            
Intangible Assets [Line Items]            
Percentage of royalties     2.00%      
Percentage of sublicense fees     15.00%      
Top of Range [Member]            
Intangible Assets [Line Items]            
Percentage of royalties     3.00%      
Percentage of sublicense fees     20.00%      
Yeda [Member]            
Intangible Assets [Line Items]            
Remaining liability     $ 127      
License Agreement [Member]            
Intangible Assets [Line Items]            
Receipt of investment   $ 5,000